Table 1.
Clinical characteristics of the 26 human immunodeficiency virus (HIV)-infected patients and the 11 controls.
| Sex | Age (years) | CD4 count (cells/µl) week 0 | CD4 count (cells/µl) week 24 | HIV-RNA (copies/ml) week 0 | HIV-RNA (copies/ml) week 24 | HIV-related illness | HAART | |
|---|---|---|---|---|---|---|---|---|
| Patient no. | ||||||||
| 1 | m | 44 | 44 | 246 | 221 000 | 40 | PCP, Karposi's sarcoma | TDF, FTC, LPV, RTV |
| 2 | m | 44 | 270 | 360 | 472 | 40 | ABV, 3TC, AZV, RTV | |
| 3 | m | 52 | 74 | 345 | 1 000 000 | 40 | ABV, 3TC, AZV, RTV | |
| 4 | f | 26 | 32 | ND | 106 000 | ND | PCP, TB | TDF, FTC, LPV, RTV |
| 5 | m | 45 | 51 | 191 | 40 900 | 40 | 3TC, AZT, D4T | |
| 6 | m | 47 | 217 | 325 | 433 000 | 40 | ABV, 3TC, AZV, RTV | |
| 7 | m | 43 | 368 | 280 | 999 000 | 51 | ABV, 3TC, D4T | |
| 8 | m | 43 | 220 | 455 | 269 000 | 40 | TDF, FTC, LPV, RTV | |
| 9 | f | 31 | 263 | 655 | 74 500 | 40 | 3TC, AZT, LPV, RTV | |
| 10 | m | 35 | 253 | 429 | 46 300 | 40 | ABV, 3TC, D4T | |
| 11 | m | 34 | 261 | 602 | 323 000 | 67 | Karposi's sarcoma | ABV, 3TC, D4T |
| 12 | f | 38 | 23 | 218 | 84 100 | 40 | 3TC, DDI, LPV, RTV | |
| 13 | m | 25 | 210 | 430 | 40 568 | 39 | TDF, FTC, D4T | |
| 14 | m | 69 | 194 | 329 | 262 000 | 40 | ABV, 3TC, D4T | |
| 15 | m | 40 | 55 | 275 | 747 000 | 40 | PCP | ABV, 3TC, D4T |
| 16 | m | 47 | 190 | 630 | 484 795 | 83 | 3TC, AZT, LPV, RTV | |
| 17 | m | 37 | 224 | 321 | 214 000 | 40 | TDF, FTC, D4T | |
| 18 | m | 31 | 271 | 486 | 45 700 | 40 | ABV, 3TC, D4T | |
| 19 | m | 27 | 204 | 321 | 97 600 | 40 | ABV, 3TC, D4T | |
| 20 | m | 27 | 220 | 530 | 118 670 | 40 | TDF, FTC, D4T | |
| 21 | m | 61 | 280 | 330 | 8 637 | 39 | ABV, 3TC D4T | |
| 22 | f | 25 | 180 | 295 | 30 700 | 40 | 3TC, AZT, LPV, RTV | |
| 23 | m | 48 | 206 | 422 | 65 800 | 40 | TDF, FTC, LPV, RTV | |
| 24 | m | 31 | 231 | 308 | 14 700 | 44 | ABV, 3TC, AZV, RTV | |
| 25 | m | 50 | 143 | 201 | 1 000 000 | 40 | ABV, 3TC, AZV, RTV | |
| 26 | m | 39 | 160 | 241 | 44 300 | 40 | TDF, FTC, LPV, RTV | |
| Median | 40 | 208 | 329 | 101 800 | 40 | |||
| Control no. | ||||||||
| 1 | m | 47 | 731 | |||||
| 2 | m | 36 | ND | |||||
| 3 | f | 39 | 698 | |||||
| 4 | m | 47 | 1088 | |||||
| 5 | m | 27 | 721 | |||||
| 6 | m | 34 | 781 | |||||
| 7 | m | 68 | 910 | |||||
| 8 | m | 25 | 529 | |||||
| 9 | m | 33 | 509 | |||||
| 10 | m | 52 | 691 | |||||
| 11 | m | 41 | 703 | |||||
| Median | 38 | 712 | ||||||
m, male; f, female; n.d., not determined; TDF, Tenofovir; FTC, emtricitabin; LPV, lopinavir; RTV, ritonavir; ABV, abacavir; 3TC, lamivudin; AZV, atazanavir; AZT, zidovudin; D4T, efavirenz; DDI, didanosin; PCP, Pneumocystis carinii pneumonia; TB, tuberculosis; HAART, highly active anti-retroviral therapy.